GSK acquires US-based Sierra Oncology for $1.9bn
In June this year, Sierra filed a New Drug Application with the US Food and Drug Administration for momelotinib.
Oncology
Latest in
Oncology
Blueprint Medicines announces financing partnerships for $1.25bn
At the closing of the deal, Blueprint will get a total of $575m in cash.
Twist and Ildong to develop antibodies for immuno-oncology applications
Under the deal, Twist will receive upfront, milestone and royalty payments as well as annual maintenance fees.
EC grants approval for Kite’s cell therapy to treat follicular lymphoma
The latest approval is based on findings from the Phase II ZUMA-5 trial in 122 relapsed or refractory FL patients.
Astellas and Sutro partner to develop immunostimulatory ADCs
Sutro could be eligible for milestone payments of up to $422.5m for each product candidate.
EMA CHMP recommends AstraZeneca-Merck’s Lynparza for breast cancer
The latest development is based on findings from the global Phase III OlympiA trial of Lynparza.
BMS receives US FDA approval for CAR T cell therapy to treat B-cell lymphoma
Breyanzi’s indication will include people whose LBCL is refractory to initial chemoimmunotherapy or relapse within a year.
Turning Point Therapeutics and MD Anderson collaborate to advance cancer therapies
The alliance agreement covers preclinical and clinical studies to be undertaken collaboratively in several solid tumours.